SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in Chicago at the American College of Rheumatology (ACR) Convergence 2025 meeting.
Read more at globenewswire.comNkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
Provided By GlobeNewswire – Last update: